This article is more than 5 years old. Information may no longer be current.

HA derivative dermal filler improves FVLS, WSRS scores

A hyaluronic acid derivative dermal filler was well-tolerated and yielded natural improvement in signs of facial aging, such as volume loss in nasolabial folds, for up to 1 year after treatment, according to researchers.

Twenty female patients between the ages of 30 and 65 years received Ial-System Duo (cross-linked hyaluronic acid + ACP 2.5%, Fidia Farmaceutici) injections to the nasolabial folds or malar region for the treatment of facial defects due to volume loss. Maximum injection volume allowed for the first treatment was between 2 mL and 4 mL. Patient follow-up visits occurred at days 7 and 14 and again at 1, 3, 6, 9 and 12 months. The study’s primary effectiveness endpoints were wrinkle severity improvement, as measured by the Wrinkle Severity Rating Scale (WSRS), and facial volume, as measured by the Facial Volume Loss Scale (FVLS) by 6 and 12 months after the initial treatment.

At baseline, the researchers rated the nasolabial folds as extreme in 30% of patients, severe in 50% and moderate in 20%. Mean WSRS score was 4.1.

After 3 months, WSRS scores decreased by 1.3 points, and the reduction was still clinically by 12 months, according to researchers.

Compared with baseline, the FVLS visual score was reduced significantly at each follow-up, with a reduction of 38% at 2 weeks, 40% at 1 month, 45% at 3 and 6 months, and 10% at 12 months. This corresponded to a visual score reduction of at least one grade in 100% of treated cases up to 3 months and in 61% of treated cases after 9 months.

Patients experienced no adverse events. Post-treatment erythema resolved in the majority of patients within 2 to 3 hours. Edema resolved with 3 to 4 hours, and bruising was primarily in the malar region and lasted 10 to 15 days. Pain was more intense in the nasolabial area and prominent during the injection procedure and lasted 1 to 2 minutes.

Final tolerance of the study product was rated as good to very good in 100% of treated patients, according to the researchers. – by Abigail Sutton

Disclosures: The researchers report no relevant financial disclosures.